Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$1.4b

Intellia Therapeutics Valuation

Is NTLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NTLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NTLA?

Key metric: As NTLA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NTLA. This is calculated by dividing NTLA's market cap by their current revenue.
What is NTLA's PS Ratio?
PS Ratio31x
SalesUS$43.09m
Market CapUS$1.44b

Price to Sales Ratio vs Peers

How does NTLA's PS Ratio compare to its peers?

The above table shows the PS ratio for NTLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.9x
MYGN Myriad Genetics
1.7x7.2%US$1.4b
MDXG MiMedx Group
3.9x9.7%US$1.4b
TVTX Travere Therapeutics
7.6x31.7%US$1.5b
GYRE Gyre Therapeutics
10.5xn/aUS$1.1b
NTLA Intellia Therapeutics
31x67.2%US$1.4b

Price-To-Sales vs Peers: NTLA is expensive based on its Price-To-Sales Ratio (31x) compared to the peer average (5.9x).

Price to Sales Ratio vs Industry

How does NTLA's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
3.9x2.4%US$109.25b
BIIB Biogen
2.4x1.3%US$22.65b
MRNA Moderna
2.8x7.2%US$14.35b
INCY Incyte
3.4x8.9%US$13.59b
NTLA 31.0xIndustry Avg. 10.1xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NTLA is expensive based on its Price-To-Sales Ratio (31x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is NTLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NTLA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio31x
Fair PS Ratio0.05x

Price-To-Sales vs Fair Ratio: NTLA is expensive based on its Price-To-Sales Ratio (31x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NTLA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$13.12
US$59.78
+355.6%
43.3%US$128.00US$14.00n/a27
Nov ’25US$14.81
US$64.33
+334.4%
46.1%US$144.00US$14.00n/a27
Oct ’25US$19.20
US$67.48
+251.5%
40.9%US$144.00US$24.00n/a27
Sep ’25US$22.44
US$69.12
+208.0%
40.1%US$144.00US$24.00n/a26
Aug ’25US$25.14
US$70.26
+179.5%
38.1%US$144.00US$24.00n/a26
Jul ’25US$22.47
US$70.26
+212.7%
38.1%US$144.00US$24.00n/a26
Jun ’25US$21.38
US$70.26
+228.6%
38.1%US$144.00US$24.00n/a26
May ’25US$22.50
US$71.16
+216.3%
38.0%US$144.00US$24.00n/a25
Apr ’25US$27.22
US$71.52
+162.7%
37.7%US$144.00US$24.00n/a25
Mar ’25US$32.66
US$70.40
+115.6%
37.4%US$144.00US$24.00n/a25
Feb ’25US$25.26
US$76.08
+201.2%
35.7%US$145.00US$29.00n/a25
Jan ’25US$30.49
US$76.36
+150.4%
36.0%US$145.00US$29.00n/a25
Dec ’24US$30.84
US$76.36
+147.6%
36.0%US$145.00US$29.00n/a25
Nov ’24US$25.50
US$83.04
+225.6%
34.5%US$157.00US$38.00US$14.8125
Oct ’24US$31.62
US$84.88
+168.4%
33.2%US$157.00US$38.00US$19.2025
Sep ’24US$37.69
US$83.58
+121.7%
33.5%US$157.00US$38.00US$22.4426
Aug ’24US$40.96
US$86.81
+111.9%
34.3%US$154.00US$44.00US$25.1426
Jul ’24US$40.78
US$87.19
+113.8%
34.2%US$154.00US$44.00US$22.4726
Jun ’24US$38.16
US$87.27
+128.7%
34.3%US$154.00US$44.00US$21.3826
May ’24US$37.74
US$92.57
+145.3%
36.7%US$168.00US$39.00US$22.5028
Apr ’24US$37.27
US$94.30
+153.0%
36.6%US$168.00US$39.00US$27.2227
Mar ’24US$40.75
US$95.62
+134.6%
36.3%US$168.00US$39.00US$32.6626
Feb ’24US$43.15
US$103.65
+140.2%
35.2%US$167.00US$39.00US$25.2626
Jan ’24US$34.89
US$108.12
+209.9%
34.4%US$173.00US$48.00US$30.4926
Dec ’23US$45.80
US$109.70
+139.5%
33.1%US$173.00US$48.00US$30.8427
Nov ’23US$53.21
US$116.05
+118.1%
36.5%US$207.00US$50.00US$25.5027

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%